Healthcare Services

Non-Insulin Therapies For Diabetes Market Expansion Outlook Through 2030 With Revenue Growth Insights

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Non-Insulin Therapies For Diabetes Market Become By 2030 Compared To 2026?

The non-insulin therapies for diabetes market size has demonstrated robust growth in recent years. It is anticipated to increase from $21.21 billion in 2025 to $22.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.5%. The expansion observed historically can be ascribed to factors such as the high prevalence of type 2 diabetes, a dependency on oral hypoglycemic agents, insufficient patient adherence to insulin therapy, an increase in hospital and retail pharmacy distribution, and the advent of various drug classes.

The non-insulin therapies for diabetes market is projected to experience substantial expansion in the upcoming years. This market is forecast to reach $28.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. Factors contributing to this growth during the projected timeframe include the increasing adoption of non-insulin drug combinations, wider utilization of GLP-1 and SGLT2 inhibitors, the broadening of online pharmacy channels, the expansion of personalized and precision medicine strategies, and the evolving integration of digital health and remote patient monitoring. Key trends anticipated during this period encompass a surge in personalized diabetes management adoption, increased deployment of AI-driven glucose monitoring systems, the expanding integration of telemedicine-linked therapy solutions, broader implementation of data-driven clinical decision support, and the progressive deployment of connected devices for remote patient care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp

What Major Growth Factors Are Impacting The Non-Insulin Therapies For Diabetes Market?

The rising incidence of diabetes is anticipated to stimulate the expansion of non-insulin therapies for the diabetes market in the future. Diabetes, a chronic medical condition, is defined by elevated blood glucose levels, resulting from the body’s inability to adequately produce or utilize insulin. The increasing number of diabetes cases is attributed to factors such as inactive lifestyles, poor dietary habits, genetic susceptibility, an aging demographic, obesity, ethnic background, insufficient public awareness, restricted access to medical services, and various environmental influences. Non-insulin treatments for diabetes address the condition by enhancing insulin sensitivity, decreasing hepatic glucose production, boosting glucose absorption in muscle cells, and generally improving blood sugar management. As an illustration, data from the UK’s Office for Health Improvement & Disparities revealed that in March 2024, the documented prevalence of type 2 diabetes among adults aged 17 and above reached 7.0%, marking an increase from 6.8% in March 2023. Consequently, the heightened prevalence of diabetes is propelling the expansion of non-insulin therapies for the diabetes market.

How Does Segment Analysis Break Down The Non-Insulin Therapies For Diabetes Market Structure?

The non-insulin therapies for diabetes market covered in this report is segmented –

1) By Type: Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP 4 Inhibitors, GLP 1 Analogs Or Agonists, SGLT2 Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals Or Clinics, Homecare Or Patients, Other End-Users

Subsegments:

1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs

2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide

3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone

4) By DPP 4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin

5) By GLP 1 Analogs Or Agonists: Exenatide, Liraglutide, Dulaglutide

6) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

Which Trends Are Influencing The Direction Of The Non-Insulin Therapies For Diabetes Market?

Leading companies within the non-emergency medical transportation market are concentrating on developing advanced solutions, such as AI-driven transportation management systems, to improve streamlined scheduling, route optimization, and operational efficiency when transporting patients for medical care. An AI-powered transportation management system is a digital platform that utilizes artificial intelligence to automate and enhance scheduling, routing, and resource allocation for transportation operations, thereby boosting efficiency through real-time decision-making and reduced delays while also elevating overall fleet performance. For example, in September 2024, MediDrive, a US-based provider of non-emergency medical transportation services, launched its Healthcare-Focused Intelligent Patient Transportation Coordination Platform, a Transportation Management System (TMS) designed to address significant challenges in patient transport and access to care. This system enables hospitals, health plans, and care coordinators to schedule and manage rides through a unified interface, offering capabilities such as real-time dispatch, AI-powered route optimization, vehicle selection across multiple mobility needs (ambulatory, wheelchair, stretcher, VIP), cost controls, and live tracking, ultimately improving on-time performance, patient compliance, and continuity of care.

Who Are The Prominent Players Across The Non-Insulin Therapies For Diabetes Market?

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

Access The Complete Non-Insulin Therapies For Diabetes Market Report:

https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report

Which Region Commands The Largest Share Of The Non-Insulin Therapies For Diabetes Market?

North America was the largest region in the non-insulin therapies for diabetes market in 2025. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Non-Insulin Therapies For Diabetes Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp

Browse Through More Reports Similar to the Global Non-Insulin Therapies For Diabetes Market 2026, By The Business Research Company

Patient Transport Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/patient-transport-services-global-market-report

Healthcare Transportation Service Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/healthcare-transportation-service-global-market-report

Alternate Transportation Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/alternate-transportation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795